NCT06017609 (POWER-HF) is a Phase 2 clinical trial of JTT-861 Capsules in Chronic Heart Failure, sponsored by Akros Pharma Inc..

Who is sponsoring NCT06017609?

NCT06017609 is sponsored by Akros Pharma Inc..

What drugs are being tested in NCT06017609?

Interventions in NCT06017609: JTT-861 Capsules, Placebo Capsules.

What condition does NCT06017609 study?

NCT06017609 studies Chronic Heart Failure.

Is NCT06017609 still recruiting?

NCT06017609 is currently completed. Last updated 21 May 2026.

Last reviewed 2026-05-21 · How we verify

NCT06017609: POWER-HF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of JTT-861 Administered for 12 Weeks in Subjects With Heart Failure With Reduced Ejection Fraction

Completed Phase 2 Last updated 21 May 2026

What this trial tests

Phase 2 trial testing JTT-861 Capsules in Chronic Heart Failure in 314 participants. Completed in 18 May 2026.

Timeline

20 December 2023

Primary endpoint
18 May 2026

18 May 2026

Quick facts

Lead sponsor	Akros Pharma Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	314
Start date	20 December 2023
Primary completion	18 May 2026
Estimated completion	18 May 2026
Sites	75 locations across United States, Bulgaria, Czechia, Poland, Romania, Spain

Drugs / interventions tested

JTT-861 Capsules — full drug profile →
Placebo Capsules — full drug profile →

Conditions studied

Chronic Heart Failure — all drugs for Chronic Heart Failure →

Sponsor

Akros Pharma Inc. — full company profile →

Who can join

Adults 30 to 85, any sex, with Chronic Heart Failure. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change from baseline to end of treatment (EOT) in left ventricular ejection fraction (LVEF) as assessed by two-dimensional echocardiography (2D-echo)
Time frame: 12 Weeks
Change from baseline to EOT in left ventricular end-systolic volume (LVESV) index as assessed by 2D-echo
Time frame: 12 Weeks
Change from baseline to EOT in left ventricular end-diastolic volume (LVEDV) index as assessed by 2D-echo
Time frame: 12 Weeks
Change from baseline to EOT in left atrial volume (LAV) as assessed by 2D-echo
Time frame: 12 Weeks
Change from baseline to EOT in N-terminal pro b-type natriuretic peptide (NT-pro-BNP) values
Time frame: 12 Weeks
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) scores from baseline
Time frame: 16 Weeks
General Scoring Guideline: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent

Sponsor's own description

This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF) who are on a stable, guideline-directed medical therapy for heart failure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Chronic Heart Failure

Currently open trials in the same condition.

NCT07265349 — A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure · Phase 1, PHASE2 · recruiting
NCT07379840 — A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South K · recruiting
NCT07325942 — Effectiveness of Low -Versus High -Volume High -Intensity Interval Training in Patients With Chronic Heart Failure · NA · recruiting
NCT07434193 — Biventricular or Left Bundle Branch Pacing to Assess the Effect of Cardiac Resynchronization Therapy in Patients Undergo · NA · recruiting
NCT07405944 — Vericiguat and Reverse Remodeling Indices in Heart Failure · Phase 4 · recruiting

Other Akros Pharma Inc. trials

Trials by the same sponsor.

NCT04465877 — Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes · Phase 1 · completed
NCT03832738 — Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis · Phase 2 · completed
NCT03358290 — Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis · Phase 2 · terminated
NCT02919475 — Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06017609 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Akros Pharma Inc.
Last refreshed: 21 May 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06017609.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing